Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.

Cross-linked N-telopeptide of type I collagen predicts bone metastasis in lung cancer

06 Dec 2017

Elevated levels of cross-linked N-telopeptide of type I collagen (NTx) appear to raise the risk of development and progression of bone metastasis (BM) in lung cancer patients, a recent study reveals.

The research team performed a meta-analysis of 11 studies (n=1,108) that compared the expression levels of NTx between lung cancer patients with and without BM. Aside from a review of study references, the databases of Web of Science, CNKI, Wangfang, PubMed and Embase were accessed for the present study.

Pooled findings from eight studies showed that patients positive for BM had significantly higher serum NTx concentrations than their BM-negative counterparts (weighted mean difference [WMD], -11.57 percent; 95 percent CI, -15.14 to -8.00).

Similarly, urinary levels of NTx, investigated in three studies, were also found to be significantly higher in patients with BM than those without (WMD, -65.15 percent; -88.33 to -41.97).

The pooled sensitivity and specificity of serum NTx in discerning BM from non-BM lung cancer patients were 0.74 (0.67 to 0.79) and 0.85 (0.80 to 0.89), respectively. In comparison, the corresponding values for urinary NTx were 0.77 (0.67 to 0.86) and 0.81 (0.76 to 0.86).

Both serum and urinary NTx had similar and good diagnostic accuracy, with respective diagnostic odds ratios of 15.07 (9.6 to 23.65) and 15.25 (8.38 to 27.73). The respective areas under the receiver operating curve for both were 0.8889 and 0.8655, which suggests that both samples could accurately distinguish between patients with and without BM.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.